Devazepide (L-364718) inhibits growth and increases expression of tumor markers in HT29-S-B6 cells.
Devazepide (L-364718, a non-peptide antagonist of CCK-A receptors), inhibits the proliferation and induces morphologic changes in the mucous-secreting, autonomously proliferating human cancer colon cell line (HT29-S-B6. Addition of devazepide (10 microM) for at least 3 days in the exponential phase of growth enhanced the baseline production of gastric M1 mucins 2-3-fold and that of carcinoembryonic antigens 5-fold. Moreover, devazepide induced an increase in the amount of the MUC-5AC mRNA expressed by HT29-S-B6 cells. The increased in mucins secretion induced by devazepide was persistent after removal and independent of the presence of serum. In conclusion, devazepide-L-364718 behaves as a maturation agent in the cell clone HT29-S-B6.
Forgue-Lafitte
M E
ME
INSERM U. 55, hôpital Saint-Antoine, Paris, France.
Coudray
A M
AM
Aubert
J P
JP
Gespach
C
C
Bara
J
J
D001570:Benzodiazepinones / Q000494:pharmacology*; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D002455:Cell Division / Q000187:drug effects; D002999:Clone Cells / Q000166:cytology / Q000378:metabolism; D020109:Devazepide; D005752:Gastric Mucins / Q000032:analysis* / Q000378:metabolism; D019073:HT29 Cells / Q000166:cytology* / Q000378:metabolism; D006727:Hormone Antagonists / Q000494:pharmacology*; D006801:Humans; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors*; D014407:Tumor Cells, Cultured
D001570:Benzodiazepinones; D002272:Carcinoembryonic Antigen; D005752:Gastric Mucins; D006727:Hormone Antagonists; D011949:Receptors, Cholecystokinin; D020109:Devazepide